Tag: Clinical Trials
Tecovirimat No Aid for Time to Lesion Resolution With Mpox
Additionally, interim analysis shows that the antiviral is safe but has no effect on pain among adults with mild-to-moderate clade II mpox
About One-Third Eligible for Weight Loss Drugs Meet Trial Exclusion Criteria
Most common exclusion criteria were major depressive disorder, malignant neoplasms, liver disease, uncontrolled HTN
Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
Longer progression-free survival seen with nivolumab + doxorubicin, vinblastine, and dacarbazine (AVD) versus brentuximab vedotin + AVD
2008 to 2022 Saw Rise in Industry-Sponsored Adult Cancer Clinical Trials
From 2018 to 2022, industry-to-federally sponsored trial ratio was 8.1
Once-Weekly Efsitora Noninferior to Degludec for Type 2 Diabetes
Once-weekly efsitora noninferior to once-daily degludec for decrease in mean glycated hemoglobin level
Quadruple Single Pill Superior for Resistant Hypertension
Reductions seen in mean office sitting systolic BP and sitting diastolic BP and in mean 24-hour ambulatory systolic BP
Depemokimab Cuts Exacerbation Rate in Eosinophilic Asthma
Annualized rate of exacerbations reduced across two randomized trials in severe asthma with eosinophilic phenotype
Granting Waiver for Cancer Treatment Does Not Affect Safety, Efficacy Outcomes
Similar serious adverse event rate, clinical benefit seen for patients with versus those without a waiver
NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians
89 percent of cancer centers report that cancer drugs are in short supply, most often vinblastine, etoposide, and topotecan
AI Screens Patients for Clinical Trials With Greater Accuracy Than Staff
In addition to enhanced performance, automated screening cuts costs